Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: March 6, 2008

PrimeGen Biotech and Unidym Form an Alliance to Explore Carbon Nanotubes in Stem Cell Medicine

(Nanowerk News) PrimeGen Biotech LLC and Unidym Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced a corporate alliance focused on exploring new applications for carbon nanotubes in stem cell medicine. Unidym brings to this partnership its leadership in carbon nanotube science, technology and production. In a press release last week, PrimeGen announced at the Stem Cell Summit meeting in New York City that Company researchers have, for the first time, successfully used non-viral technologies to reprogram adult human cells into stem cells that the Company refers to as intermediate iPS cells. Unlike embryonic stem cells, induced pluripotent stem cells, or iPS cells, are derived directly from a patient’s adult human tissues such as skin. PrimeGen will have access to Unidym’s extensive patent portfolio, services and industry standard HIPCO® carbon nanotubes.
“We’re excited to bring together leaders in the field of nanotechnology materials science with our talented team of stem cell researchers,” said Thomas C.K. Yuen, CEO, PrimeGen Biotech. “Our combined efforts will undoubtedly generate important advances in the field of regenerative medicine and bring us closer to the day when clinically safe and effective individualized stem cell therapies can be administered in a routine manner to patients.”
“PrimeGen’s innovative use of carbon nanotubes in cell reprogramming brings nanotube technology into a truly ground breaking field of use,” said Art Swift, Unidym’s President and CEO. “Given Unidym’s extensive experience with carbon nanotubes and our foundational patent portfolio, this alliance uniquely leverages the natural synergies between our companies. We look forward to helping PrimeGen advance its breakthrough solution for stem cell production ultimately into clinical use as a stem-cell based therapy.”
PrimeGen has submitted its scientific findings, as abstracts, for presentation at the International Society of Stem Cell Research meeting to be held this year in Philadelphia, June 11-14. Manuscripts are also being prepared for peer-reviewed publication.
About PrimeGen Biotech LLC
PrimeGen Biotech (www.primegenbiotech.com) is dedicated to the research and therapeutic applications of adult stem cells, leading to individualized patient therapies. Entering its fifth year of operations at the pre-clinical stage of product development, the company specializes in two core technologies: germ line stem cells and therapeutic reprogramming. Pioneering work on induced pluripotent stem cells (iPS cells), positions PrimeGen as a leader in moving this breakthrough from research to therapy. Future applications of both PrimeGen core technologies will enlist a patient’s own adult tissue cells to generate stem cells for regenerative and restorative medical treatments. Based in Irvine, California, PrimeGen Biotech is a privately held, Delaware limited liability company.
About Unidym
Unidym (www.unidym.com) is a leader in the manufacture and application of carbon nanotubes (CNTs), a novel material with extraordinary electrical, thermal, and mechanical properties. Unidym provides bulk materials, CNT-enabled products, and intellectual property to a wide range of customers and business partners. As a result of its recent merger with CNI, Unidym possesses a foundational patent portfolio that covers nearly every aspect of CNT manufacturing and processing as well as multiple product applications.
Unidym is focused on the electronics industry where its initial products include transparent electrodes for touch screens, flat panel displays, solar cells, and solid state lighting; electrodes for fuel cells; and thin film transistors for printable electronics. Unidym is also pursuing an aggressive, cross-industry partnership strategy to capture value from the wide ranging uses of CNTs. Unidym’s licensing program, technical expertise and manufacturing facilities can enable partners to rapidly develop CNT solutions for their specific applications. Unidym is a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR).
About Arrowhead Research Corp.
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Source: PrimGen Biotech
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
 
 
These articles might interest you as well: